ANGPTL2 and osteosarcoma: For example, pharmaceutical inhibition of ANGPTL2 signaling using a non-RGD-based integrin-binding peptide (ATN-161) could be a potential strategy for interfering with lung PMN formation in osteosarcoma, as suggested by preclinical studies (213).